🏥 Last week in Kiang Wu Hospital, Macau a dedicated workshop “iVAC 2L”, was organized with…
We have a mission!
PulseCath® is focused on developing ground-breaking technologies designed to assist the life sustaining pumping functions of the failing heart.
Take a look at our products
Now also available in the
App Store, download here:
SEE OUR
Facts & Figures
Registrations
> 50 countries approved registrations
Cases
> 175 shared cases on LinkedIn; > 400 reported cases
> 1.300 iVAC 2L sold
> 35 distributor agreements
Hospitals
> 45 hospitals use iVAC 2L on a regular base; > 9 Centers of Excellence.
Patients
> 600 patients world wide treated by iVAC 2L
Clinical evidence
> 30 publications
Indication
The iVAC 2L is intended for use in patients with impaired left ventricular function which require left ventricular mechanical circulatory support for up to 24 hours
11-03-2024
PulseCath Achieves MDR CE Certification for iVAC 2L
26-01-2024
Exciting News: First Patient Enrolled in the UNLOAD CHIP trial at Amsterdam VU Medical Center, the Netherlands
07-12-2023
Romanian CTO Workshop in Oradea with live case iVAC 2L
25-10-2023
First successful iVAC 2L case in China (Hainan Boao)
MEET OUR
Medical advisors
Clinical programme supported by leading cardiologists